Literature DB >> 17350111

The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006.

I G Barr1, A C Hurt, N Deed, P Iannello, C Tomasov, N Komadina.   

Abstract

The adamantanes (amantadine and rimantadine) were the first antivirals licensed for use against influenza A viruses and have been used in some countries to control seasonal influenza. While increasing resistance of A(H3) viruses to this class of drug has been reported in recent years, only low levels of resistance were seen with A(H1) viruses until the 2005-2006 influenza season in the USA. In this study we analysed 101 human influenza A viruses isolated in 2006 that were referred to the WHO Collaborating Centre for Reference and Research in Melbourne, from Australia and the surrounding regions, for evidence of resistance to adamantanes. We found that whereas previously A(H1) resistant viruses were rare, 21.8% of the 2006 viruses had a resistant genotype. By comparison, 58.6% of influenza A(H3) viruses isolated in 2006 that were tested at the Centre, had a resistant genotype.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17350111     DOI: 10.1016/j.antiviral.2007.01.006

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  17 in total

1.  Distribution and dynamics of adamantanes in a lipid bilayer.

Authors:  Chee Foong Chew; Andrew Guy; Philip C Biggin
Journal:  Biophys J       Date:  2008-10-03       Impact factor: 4.033

Review 2.  Emerging viral diseases.

Authors:  Andrew Pekosz; Gregory E Glass
Journal:  Md Med       Date:  2008

3.  Antiviral activity of the effective monomers from Folium Isatidis against influenza virus in vivo.

Authors:  Zhao Liu; Zhan-qiu Yang; Hong Xiao
Journal:  Virol Sin       Date:  2011-01-10       Impact factor: 4.327

4.  Antiviral Action of Methylated β-Lactoglobulin on the Human Influenza Virus A Subtype H3N2.

Authors:  Mahmoud Sitohy; Bernard Besse; Sylviane Billaudel; Thomas Haertlé; Jean-Marc Chobert
Journal:  Probiotics Antimicrob Proteins       Date:  2010-06       Impact factor: 4.609

5.  Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.

Authors:  Katja Bauer; Ralf Dürrwald; Michael Schlegel; Kathrin Pfarr; Dominik Topf; Nadine Wiesener; Hans-Martin Dahse; Peter Wutzler; Michaela Schmidtke
Journal:  Med Microbiol Immunol       Date:  2011-06-19       Impact factor: 3.402

Review 6.  Amantadine and rimantadine for influenza A in children and the elderly.

Authors:  Márcia G Alves Galvão; Marilene Augusta Rocha Crispino Santos; Antonio J L Alves da Cunha
Journal:  Cochrane Database Syst Rev       Date:  2014-11-21

7.  Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method.

Authors:  Varough M Deyde; Tung Nguyen; Rick A Bright; Amanda Balish; Bo Shu; Stephen Lindstrom; Alexander I Klimov; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2009-01-05       Impact factor: 5.191

Review 8.  A Review of the Antiviral Susceptibility of Human and Avian Influenza Viruses over the Last Decade.

Authors:  Ding Yuan Oh; Aeron C Hurt
Journal:  Scientifica (Cairo)       Date:  2014-04-02

9.  The origin and global emergence of adamantane resistant A/H3N2 influenza viruses.

Authors:  Martha I Nelson; Lone Simonsen; Cécile Viboud; Mark A Miller; Edward C Holmes
Journal:  Virology       Date:  2009-04-24       Impact factor: 3.616

10.  Pandemic influenza: implications for occupational medicine.

Authors:  W Shane Journeay; Matthew D Burnstein
Journal:  J Occup Med Toxicol       Date:  2009-06-23       Impact factor: 2.646

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.